Circio invites to corporate update webcast on 26 March 2025
- CEO Dr. Erik D Wiklund will provide a general company update and present the most recent circVec experimental data and R&D strategy
- CFO Dr. Lubor Gaal will present the 2024 financial results (unaudited) and provide an update on Circio's corporate development activities
Oslo, Norway 19 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CET on Wednesday 26 March 2025. In the webcast, Circio management will provide a corporate update and present the latest developments for the circVec platform technology.
The webcast will include an overview of ongoing testing with the novel circVec 3.0 generation, AAV and non-viral gene therapy vector development, and tissue-specific circVec expression data in vivo, as well as an outlook on experimental plans and milestones.
The corporate section will cover Circio's 2024 financial results (unaudited) and provide an update on financing and business development activities for 2025.
Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal
Time: 10:00 CET on 26 March 2025
click here to access the Teams webcast
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ
Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#
Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage